|Bid||8.25 x 1100|
|Ask||8.25 x 800|
|Day's Range||8.25 - 8.35|
|52 Week Range||6.75 - 15.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.71|
Cytokinetics, Incorporated (CYTK) today announced data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) were presented in an oral presentation by John W. Day, M.D., Ph.D., Professor of Neurology and Pediatrics (Genetics), Stanford University, at the 2018 Annual Cure SMA Conference in Dallas. In collaboration with Astellas, Cytokinetics is developing reldesemtiv as a potential treatment for people with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue. The study, which examined two dose levels of reldesemtiv, 150 mg or 450 mg twice daily, demonstrated dose-dependent increases in 6MWD in ambulatory patients as measured at both post-baseline time points, week four and week eight.
Cytokinetics, Inc. (CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 20, 2018 at 11:00 AM EDT at the St. Regis Hotel in New York. The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of the event. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
Cytokinetics (NASDASQ:CYTK) looks to turn around their fortunes following last year’s unsuccessful readout of Tirasemtiv in ALS. The company’s follow on asset Reldesemtiv, is built on the same mechanism but looks to resolve the dropout issue. Further, the drug seems to be more potent than its predecessor, which may help amplify the signal we saw in respiratory function.
Cytokinetics, Incorporated (CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented in an oral presentation at the 2018 Annual Cure SMA Conference in Dallas on June 16, 2018. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
Looking to add potential meaningful upside to your portfolio, but unsure where to start? Stocks such as Globant and Cytokinetics are considered to be high growth in terms of howRead More...
Investors in Cytokinetics (CYTK) need to pay close attention to the stock based on moves in the options market lately.
Cure SMA and Cytokinetics today announced an expanded partnership to increase education, awareness and fundraising for spinal muscular atrophy (SMA). As a National Platinum Partner for 2018, Cytokinetics will lend support to several of Cure SMA’s initiatives at both the local and national level to advance understanding of, and research toward potential treatments for SMA, a genetic disease that robs people of physical strength and takes away their ability to walk, eat or breathe. Cytokinetics will sponsor the 2018 Annual SMA Conference as a Visionary Sponsor, increasing support for this unique event which brings together families affected by SMA, along with researchers and clinicians, to network, learn, and collaborate.
Cytokinetics, Incorporated (CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 16, 2018 at 10:30 AM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South San Francisco, CA. Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics’ performance. Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com.
Cytokinetics, Incorporated (CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. “We have enjoyed our longstanding, successful collaboration with The ALS Association and look forward to continuing our partnership to support the ALS community,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer.
LONDON, UK / ACCESSWIRE / April 30, 2018 / Active-Investors.com has just released a free research report on Zealand Pharma A/S (NASDAQ: ZEAL) ("Zealand"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZEAL as the Company's latest news hit the wire. On April 26, 2018, the Company announced that it has successfully concluded the End-of-Phase-2 meeting with the US Food and Drug Administration (FDA) regarding the Phase-3 program for Zealand's long-acting GLP-2 analog, glepaglutide, in short bowel syndrome (SBS) patients.
The South San Francisco, California-based company said it had a loss of 56 cents per share. The biopharmaceutical company posted revenue of $5.3 million in the period. Cytokinetics shares have declined ...
Completed Enrollment in Phase 2 Study of Reldesemtiv in Patients with SMA; Data Expected in Q2 2018. Preparing to Initiate Second Phase 3 Clinical Trial of Omecamtiv Mecarbil. SOUTH SAN FRANCISCO, Calif., ...
Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of Cytokinetics Incorporated (NASDAQ:CYTK) as an investment opportunity. Anyone interested inRead More...
Cytokinetics, Incorporated (CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented by John Day, M.D., Ph.D., Professor of Neurology and Pediatrics (Genetics), Stanford University Medical Center, in an oral presentation at the 2018 Annual Cure SMA Conference in Dallas on June 16, 2018. The clinical study is designed to assess the effect of reldesemtiv, a next-generation fast skeletal muscle troponin activator (FSTA), on multiple measures of muscle function in both ambulatory and non-ambulatory patients with SMA. In collaboration with Astellas Pharma Inc. (TSE:4503) (“Astellas”), Cytokinetics is developing reldesemtiv as a potential treatment for people living with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.
SOUTH SAN FRANCISCO, Calif., April 12, 2018-- Cytokinetics, Incorporated today announced that it is scheduled to report first quarter results on April 26, 2018 at 4:00 PM Eastern Time. Following the announcement, ...
On a per-share basis, the South San Francisco, California-based company said it had a loss of 75 cents. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed ...
NEW YORK, NY / ACCESSWIRE / February 15, 2018 / Cytokinetics, Incorporated (NASDAQ: CYTK ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 15, 2018 at 4:30 PM ...
Today, I will be analyzing Cytokinetics Incorporated’s (NASDAQ:CYTK) recent ownership structure, an important but not-so-popular subject among individual investors. When it comes to ownership structure of a company, the impactRead More...
Cytokinetics (NASDAQ: CYTK ) announces its next round of earnings Thursday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement. Earnings and Revenue Sell-side analysts ...